Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Recombinant human activated protein C in experimental models of acute lung injury: the timing is critical!

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Liaw PC (2004) Endogenous protein C activation in patients with severe sepsis. Crit Care Med 32:S214–S218

  2. 2.

    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709

  3. 3.

    Richard J-C, Bregeon F, Leray V, Le Bars D, Costes N, Tourvieille C, Lavenne F, Devouassoux-Shisheboran M, Gimenez G, Guerin C (2007) Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury. Intensive Care Med DOI 10.1007/s00134-007-0782-0

  4. 4.

    Schuster DP (1994) ARDS: clinical lessons from the oleic acid model of acute lung injury. Am J Respir Crit Care Med 149:245–260

  5. 5.

    Rosenthal C, Caronia C, Quinn C, Lugo N, Sagy M (1998) A comparison among animal models of acute lung injury. Crit Care Med 26:912–916

  6. 6.

    Hill LL, Chen DL, Kozlowski J, Schuster DP (2004) Neutrophils and neutrophil products do not mediate pulmonary hemodynamic effects of endotoxin on oleic acid-induced lung injury. Anesth Analg 98:452–457

  7. 7.

    Gust R, Kozlowski J, Stephenson AH, Schuster DP (1998) Synergistic hemodynamic effects of low-dose endotoxin and acute lung injury. Am J Respir Crit Care Med 157:1919–1926

  8. 8.

    Chen DL, Schuster DP (2004) Positron emission tomography with [18F]fluorodeoxyglucose to evaluate neutrophil kinetics during acute lung injury. Am J Physiol Lung Cell Mol Physiol 286:L834–840

  9. 9.

    Jian MY, Koizumi T, Tsushima K, Fujimoto K, Kubo K (2005) Activated protein C attenuates acid-aspiration lung injury in rats. Pulm Pharmacol Ther 18:291–296

  10. 10.

    Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K (1996) Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 87:642–647

  11. 11.

    Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K (1997) Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 272:L197–202

  12. 12.

    Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ (2003) Expression and function of the endothelial protein C receptor in human neutrophils. Blood 102:1499–1505

  13. 13.

    Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, Zarini S, Murphy RC, Kuhn K, Richter D, Kast KR, Abraham E (2004) Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 104:3878–3885

  14. 14.

    Maybauer MO, Maybauer DM, Fraser JF, Traber LD, Westphal M, Enkhbaatar P, Cox RA, Huda R, Hawkins HK, Morita N, Murakami K, Mizutani A, Herndon DN, Traber DL (2006) Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Crit Care Med 34:2432–2438

  15. 15.

    Robriquet L, Collet F, Tournoys A, Prangere T, Neviere R, Fourrier F, Guery BP (2006) Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res 7:41

  16. 16.

    Tomashefski JF Jr (2000) Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med 21:435–466

  17. 17.

    Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W (2000) Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 161:454–462

  18. 18.

    Traber DL, Herndon DN, Enkhbaatar P, Maybauer MO, Maybauer DM (2007) The pathophysiology of inhalation injury. In: Herndon DN (ed.) Total burn care. Saunders, London, pp. 248–261

  19. 19.

    Eichacker PQ, Natanson C, Danner RL (2006) Surviving sepsis – practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 355:1640–1642

Download references

Author information

Correspondence to Marc O. Maybauer.

Additional information

No author has a conflict of interest that relates to the content discussed in this manuscript.

This editorial refers to the article available at: http://dx.doi.org/10.1007/s00134-007-0782-0.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Velik-Salchner, C., Wenzel, V., Maybauer, D.M. et al. Recombinant human activated protein C in experimental models of acute lung injury: the timing is critical!. Intensive Care Med 33, 2048–2050 (2007). https://doi.org/10.1007/s00134-007-0783-z

Download citation